Topics

GSK's tuberculosis vaccine shows efficacy over three years in HIV negative patients

07:48 EDT 29 Oct 2019 | Pharmafile

Promising results have been revealed from a GlaxoSmithKline study, conducted in partnership with non-profit scientific research organisation IAVI, investigating the efficacy of the company’s M72/AS01E tuberculosis (TB) vaccine in HIV-negative adults with latent TB infection.

The study was conducted across 11 sites throughout Kenya, South Africa and Zambia – all TB-endemic regions – enrolling 3,573 HIV-negative participants between 18 and 50 years old.

read more

Original Article: GSK's tuberculosis vaccine shows efficacy over three years in HIV negative patients

NEXT ARTICLE

More From BioPortfolio on "GSK's tuberculosis vaccine shows efficacy over three years in HIV negative patients"

Quick Search

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...